<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1908">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04366245</url>
  </required_header>
  <id_info>
    <org_study_id>PC/COVID-19</org_study_id>
    <nct_id>NCT04366245</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</brief_title>
  <official_title>Phase I / II Multicentre, Randomized and Controlled Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andalusian Network for Design and Translation of Advanced Therapies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Andalusian Network for Design and Translation of Advanced Therapies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I / II multicentre, randomized and controlled clinical trial to evaluate the efficacy
      of treatment with hyperimmune plasma obtained from convalescent antibodies of COVID-19
      infection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).</measure>
    <time_frame>30 days after enrollment</time_frame>
    <description>Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Death from any cause</measure>
    <time_frame>Day +21 after randomization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Need for mechanical ventilation</measure>
    <time_frame>Day +21 after randomization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Any of the following analytical data after 72h of randomization.</measure>
    <time_frame>Day +21 after randomization</time_frame>
    <description>IL-6&gt; 80 pg / mL, D-dimer&gt; 10 times, ferritin&gt; 1000 ng / mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: SOFA scale ≥ 3 after 72 hours of randomization or an increase of 2 points or more from the basal level</measure>
    <time_frame>Day +21 after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy. Mortality on days 14 and 28.</measure>
    <time_frame>Days 14 and 28.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Proportion of patients who required mechanical ventilation</measure>
    <time_frame>Until day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Proportion of patients who develop analytical alterations.</measure>
    <time_frame>Day +21 after randomization.</time_frame>
    <description>IL-6&gt; 80 pg / mL, D-dimer&gt; 10 times, ferritin&gt; 1000 ng / mL until the cure test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Cure / clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.</measure>
    <time_frame>Day +21 after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: PCR negative for SARS-CoV-2</measure>
    <time_frame>On days 7 and 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Proportion of patients requiring treatment.</measure>
    <time_frame>Until day 21.</time_frame>
    <description>Proportion of patients requiring treatment with Tocilizumab Sarilumab, Anakimra or other IL-6 or IL-1 antagonists, or corticosteroids at doses of methylprednisolone greater than 2 mg / Kg / day (or equivalent) and / or any investigational medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Duration of hospitalization (days)</measure>
    <time_frame>Until day 21.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample</measure>
    <time_frame>At baseline and on day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virology and immunological variables: Total antibody quantification</measure>
    <time_frame>At baseline and on days 3, 7 and 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.</measure>
    <time_frame>Before infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>SARS-CoV 2</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hyperimmune plasma</intervention_name>
    <description>PLASMA OF CONVALESCENT COVID-19</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care for SARS-CoV-2 infection</intervention_name>
    <description>Standard of care for SARS-CoV-2 infection</description>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent prior to performing procedures. the oral consent be accepted
             testified to prevent paper handling.

          2. Patient of both sexes, and ≥18 years.

          3. SARS-CoV-2 infection determined by PCR in a sample of naso-oropharyngeal exudate or
             other respiratory specimen or determination of specific positive IgM antibodies, in
             &lt;72 hours before randomization.

          4. Patients requiring hospitalization for pneumonia COVID-19 without need until
             randomization of mechanical ventilation (invasive or non-invasive), and at least one
             of the following:

               -  O2 saturation ≤ 94% in ambient air, or PaO2 / FiO2 ≤ 300 mm Hg.

               -  Age&gt; 65 years.

               -  Presence of: high blood pressure, chronic heart failure, chronic obstructive
                  pulmonary disease, liver cirrhosis, or other chronic pulmonary and cardiovascular
                  diseases, diabetes, or obesity

        Exclusion Criteria:

          1. Requirement before randomization of mechanical ventilation (invasive or non-invasive).

          2. Any of the following analytical data before randomization: IL-6&gt; 80 pg / mL, D-dimer&gt;
             10 times ULN, ferritin&gt; 1000ng / mL.

          3. Participation in another clinical trial or experimental treatment for COVID-19.

          4. In the opinion of the clinical team, progression to death or mechanical ventilation is
             highly probable within 24 hours, regardless of treatment provision.

          5. Incompatibility or allergy to the administration of human plasma.

          6. Severe chronic kidney disease grade 4 or requiring dialysis (ie eGFR &lt;30)

          7. Pregnant, lactating, or fertile women who are not using an effective method of
             contraception. It is considered a woman of childbearing age all women from 18 years
             and up to a year after the last menstrual period in the case of menopausal women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ana Cardesa Gil</last_name>
    <phone>697 95 69 41</phone>
    <phone_ext>0034</phone_ext>
    <email>ana.cardesa@juntadeandalucia.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital U. Jerez de la Frontera</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvador López Cárdenas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital U. Puerto Real</name>
      <address>
        <city>Puerto Real</city>
        <state>Cádiz</state>
        <zip>11510</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Romero Palacios</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <state>Málaga</state>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julián Olalla Sierra</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital U. Torrecárdenas</name>
      <address>
        <city>Almería</city>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inmaculada Poyato Ayuso</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital U. Puerta del Mar</name>
      <address>
        <city>Cádiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Antonio Girón González</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital U. Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Concepción López Robles</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital U. San Cecilio</name>
      <address>
        <city>Granada</city>
        <zip>18016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ismael Francisco Aomar Millán</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Ramón Jiménez</name>
      <address>
        <city>Huelva</city>
        <zip>21005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Martínez Marcos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional U. de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Márquez Gómez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital U. Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesús Santos González</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Unversitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesús Ródriguez Baño</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Aguilar Guisado</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital U. Nuestra Señora de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Macías Sánchez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital San Juan de Dios</name>
      <address>
        <city>Sevilla</city>
        <zip>41930</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana María Mata Martín</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

